United Therapeutics presented its pipeline and financial outlook at the Wells Fargo 21st Annual Healthcare Conference on September 8 2026. CEO Martine Rothblatt described the company’s strategy as “approve and then improve,” aiming to secure initial approvals for new therapies and then refine formulations or expand indications while changing only one variable at a time.
She highlighted a portfolio of 14 new products, including nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), a dry‑powder inhaler version of Tyvaso, and a soft‑mist inhaler (Tresmi) for interstitial lung disease. Oral ralinepag, a once‑daily pill for pulmonary hypertension, has a PDUFA date of June 27 2026 and was described as having “the best clinical trial data of any product in pulmonary hypertension ever.” A triple‑combination ralinepag pill, blending ralinepag with a PDE5 inhibitor and an endothelin receptor antagonist, was called the “holy grail.”
The company also discussed a collaboration with MannKind on Ralpi, an inhaled ralinepag product for interstitial lung disease, supported by a 50,000‑patient‑per‑year production facility. Additional pipeline items include a treprostinil/iloprost rescue inhaler for pulmonary hypertension and various label expansions across interstitial lung disease.
On the xenotransplantation front, United Therapeutics noted three FDA‑approved IND applications for genetically modified pig kidney and heart transplants, with initial clinical trial data expected by the end of 2027, final data by the end of 2028, and a biologics license application planned for 2029.
Financially, James Edgemond said the firm’s current revenue guidance stands at $4 billion, with $3.15 billion generated over the last twelve months. The company has launched a $500 million accelerated share repurchase, bringing near‑term buybacks to about $4 billion. It raised its operating budget cap to 55 % of prior‑year revenue, excluding business development and facilities capital spending, up from 50 % previously.
United Therapeutics cited a market capitalization of roughly $20 billion (or $21.42 billion per InvestingPro data) and projected that capturing 50 % of a combined addressable patient population of about one million could yield $50 billion to $100 billion in annual pharmaceutical revenue from its 14‑product pipeline. Other metrics shared included a current ratio of 5.73, gross profit margin of 86 %, return on equity of 19 %, P/E ratio of 17.81 and a financial‑health score of 3.38 out of 5. The stock has returned 24 % over the past year.
The presentation also noted layers of patent protection extending into the 2040s and orphan‑drug exclusivity into the 2030s for key assets.
